TP53 wild-type
|
Small Lymphocytic Lymphoma
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
PCR Sensitive: A2 - Guideline
|
PCR Sensitive: A2 - Guideline
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
FCR Sensitive: A2 - Guideline
|
FCR Sensitive: A2 - Guideline
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
alemtuzumab Sensitive: A2 - Guideline
|
alemtuzumab Sensitive: A2 - Guideline
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
rituximab Sensitive: A2 - Guideline
|
rituximab Sensitive: A2 - Guideline
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
chlorambucil Sensitive: A2 - Guideline
|
chlorambucil Sensitive: A2 - Guideline
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
venetoclax + obinutuzumab Sensitive: A2 - Guideline
|
venetoclax + obinutuzumab Sensitive: A2 - Guideline
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
CD20 inhibitor Sensitive: A2 - Guideline
|
CD20 inhibitor Sensitive: A2 - Guideline
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
rituximab + idelalisib Sensitive: A2 - Guideline
|
rituximab + idelalisib Sensitive: A2 - Guideline
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
obinutuzumab + acalabrutinib Sensitive: A2 - Guideline
|
obinutuzumab + acalabrutinib Sensitive: A2 - Guideline
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
ibrutinib + obinutuzumab Sensitive: A2 - Guideline
|
ibrutinib + obinutuzumab Sensitive: A2 - Guideline
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
zanubrutinib Sensitive: A2 - Guideline
|
zanubrutinib Sensitive: A2 - Guideline
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
TP53 wild-type
|
Small Lymphocytic Lymphoma
|
rituximab + ibrutinib Sensitive: A2 - Guideline
|
rituximab + ibrutinib Sensitive: A2 - Guideline
|
TP53 wild-type
|
CLL
|
TP53 wild-type
|
CLL
|
zanubrutinib Sensitive: A2 - Guideline
|
zanubrutinib Sensitive: A2 - Guideline
|
TP53 wild-type
|
AML
|
TP53 wild-type
|
AML
|
RO5503781 Resistant: B - Late Trials
|
RO5503781 Resistant: B - Late Trials
|
TP53 wild-type
|
Lymphoma
|
TP53 wild-type
|
Lymphoma
|
ALRN-6924 Sensitive: C2 – Inclusion Criteria
|
ALRN-6924 Sensitive: C2 – Inclusion Criteria
|
TP53 wild-type
|
Solid Tumor
|
TP53 wild-type
|
Solid Tumor
|
ALRN-6924 Sensitive: C2 – Inclusion Criteria
|
ALRN-6924 Sensitive: C2 – Inclusion Criteria
|
TP53 wild-type
|
Solid Tumor
|
TP53 wild-type
|
Solid Tumor
|
KRT-232 Sensitive: C2 – Inclusion Criteria
|
KRT-232 Sensitive: C2 – Inclusion Criteria
|
TP53 wild-type
|
AML
|
TP53 wild-type
|
AML
|
HDM201 Sensitive: C3 – Early Trials
|
HDM201 Sensitive: C3 – Early Trials
|
TP53 wild-type
|
Solid Tumor
|
TP53 wild-type
|
Solid Tumor
|
HDM201 Sensitive: C3 – Early Trials
|
HDM201 Sensitive: C3 – Early Trials
|
TP53 wild-type
|
Liposarcoma
|
TP53 wild-type
|
Liposarcoma
|
MK-8242 Sensitive: C3 – Early Trials
|
MK-8242 Sensitive: C3 – Early Trials
|
TP53 wild-type
|
Solid Tumor
|
TP53 wild-type
|
Solid Tumor
|
MK-8242 Sensitive: C3 – Early Trials
|
MK-8242 Sensitive: C3 – Early Trials
|
TP53 wild-type
|
Multiple Myeloma
|
TP53 wild-type
|
Multiple Myeloma
|
KRT-232 Sensitive: C3 – Early Trials
|
KRT-232 Sensitive: C3 – Early Trials
|
TP53 wild-type
|
Liposarcoma
|
TP53 wild-type
|
Liposarcoma
|
HDM201 Sensitive: C3 – Early Trials
|
HDM201 Sensitive: C3 – Early Trials
|
TP53 wild-type
|
Breast Cancer
|
TP53 wild-type
|
Breast Cancer
|
selinexor Sensitive: D – Preclinical
|
selinexor Sensitive: D – Preclinical
|
TP53 wild-type
|
Breast Cancer
|
TP53 wild-type
|
Breast Cancer
|
chidamide Sensitive: D – Preclinical
|
chidamide Sensitive: D – Preclinical
|
TP53 wild-type
|
AML
|
TP53 wild-type
|
AML
|
thioureidobutyronitrile Sensitive: D – Preclinical
|
thioureidobutyronitrile Sensitive: D – Preclinical
|
TP53 wild-type
|
Multiple Myeloma
|
TP53 wild-type
|
Multiple Myeloma
|
APG-115 Sensitive: D – Preclinical
|
APG-115 Sensitive: D – Preclinical
|
TP53 wild-type
|
Multiple Myeloma
|
TP53 wild-type
|
Multiple Myeloma
|
bortezomib + APG-115 Sensitive: D – Preclinical
|
bortezomib + APG-115 Sensitive: D – Preclinical
|
TP53 wild-type
|
Breast Cancer
|
TP53 wild-type
|
Breast Cancer
|
APG-115 + KRT-232 Sensitive: D – Preclinical
|
APG-115 + KRT-232 Sensitive: D – Preclinical
|
TP53 wild-type
|
Breast Cancer
|
TP53 wild-type
|
Breast Cancer
|
chidamide Sensitive: D – Preclinical
|
chidamide Sensitive: D – Preclinical
|
